# Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)

> **NCT00902018** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 20 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Romiplostim
- **OTHER:** healthy controls

## Key facts

- **NCT ID:** NCT00902018
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2015-09-07
- **Final completion:** 2015-09-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902018, "Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00902018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*